AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 191 min read$PCVX

GUGGENHIME ANDREW sold $530K of PCVX

GUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at $53.00 ($0.53M total) on 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GUGGENHIME ANDREW
Published Jun 19, 2026, 12:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 19, 2026, 12:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
high confidence
Mentioned
$PCVX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

This provides a fresh datapoint on insider activity (10,000-share open-market sale at $53) but does not introduce new company fundamentals.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and lack of new fundamentals suggest limited trading impact.

03

What to watch

Insider sales can be scheduled regardless of outlook; without accompanying buys, guidance changes, or material events, the signal is usually weak.

Relevance 4/10Novelty 3/10Timing: immediately after the SEC Form 4 filing (filed 2026-06-18)

Background

The article is an SEC Form 4 insider transaction for Vaxcyte, Inc. (PCVX) by Andrew Guggenheim (President and CFO).

Company-level read

Ticker impact

$PCVXNeutralHigh confidence
Context

SEC Form 4 shows Vaxcyte CFO sold 10,000 shares at $53 on 2026-06-18 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any reaction is likely muted.

Evidence & confidence

The disclosure is a scheduled open-market sale (Code S) with a stated 10b5-1 plan, and no new operating/financial/regulatory facts are provided.

Market effects

Sector

No sector read-across; this is a single-company insider transaction with no new clinical or regulatory information.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be purely liquidity/tax-driven under a pre-arranged 10b5-1 plan, so it may not reflect bearish expectations.

Key entities

  • public_company
    Vaxcyte, Inc.

    Issuer of the Form 4 insider transaction; CFO sold shares under a 10b5-1 plan.

  • insider
    GUGGENHIME ANDREW

    President and CFO who executed the reported sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

OCT 9
$PCVXHighAI 9/10

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte (PCVX) closed public offerings raising $1.15B, including 8.58M shares at $64 each, pre-funded warrants, and $575M in convertible notes. Proceeds will fund clinical trials, manufacturing, and R&D. Joint bookrunners included Jefferies, Leerink, and BofA.

marketscreener.com2 min
OCT 9
$MRNAHighAI 8/10

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally - Moderna (NASDAQ:MRNA), BioNTec

A new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.

benzinga.com2 min